Full-Time

Scientist / Senior Scientist In Clinical Flow Cytometry group

Posted on 5/17/2025

Deadline 6/27/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

No salary listed

Mid, Senior

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • At least 5 years of post-graduate flow cytometry experience in high-dimensional flow, receptor occupancy and functional flow
  • Be proficient with flow cytometry analysis software such as Flowjo, FCS Express, OMIQ, etc.
  • Must understand flow cytometry data analysis and interpretation
  • Understanding of validation principles for flow cytometry assays for clinical trials
  • Be proficient in writing method procedures and assay validation and study reports
  • Ability to handle multiple projects concurrently, and work in a highly matrixed team
  • Must have excellent communication, organization and record keeping skills
Responsibilities
  • Independently design, develop, optimize, validate, and execute novel flow cytometry-based assays for clinical biomarker studies
  • De novo assay design/development will be required
  • Understanding and practical implementation of flow cytometry assay/ instrument optimization
  • Perform clinical sample analysis as appropriate
  • Execution of assays may be achieved using in-house laboratories, or by working with vendor labs in an outsourcing fashion
  • Introduce and troubleshoot new flow cytometry methods and platforms
  • Accurate record keeping of experiments and procedures
  • Flow cytometry data analysis and interpretation in support of clinical team’s decision making
  • Provide technical subject matter expertise to stakeholders in the selection of flow cytometry panels
  • Interacting with stakeholders to understand the needs of individual programs, including assay and reportable specifics, timelines, and data delivery needs
  • Work with vendor labs to transfer in-house generated assays and oversee/troubleshoot/quality control data generated by external vendors
Desired Qualifications
  • Previous industry experience is a plus
  • Experience with the BD Biosciences flow cytometers and Cytek Aurora is a plus
  • A PhD in a scientific field related to immunology is a plus
  • Experience with clinical trial assays or samples from work with a pharmaceutical company or in a CRO is highly desired.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet the same quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, as well as its commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) standards.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's $40B US investment signals strong commitment to growth despite cost-cutting.
  • AI partnership with Optellum enhances early lung cancer diagnosis and precision care.
  • Expansion in Gulf region under new leadership boosts market presence and opportunities.

What critics are saying

  • Layoffs and facility closures may disrupt production and market demand fulfillment.
  • New leadership appointments could shift company policy, impacting ongoing projects.
  • Acquisition of 2seventy bio may pose integration challenges affecting operational efficiency.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases, setting it apart in biopharma.
  • The company invests heavily in R&D to develop innovative and generic medicines.
  • BMS emphasizes sustainability and ESG goals, enhancing its corporate responsibility image.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

BioSpace
May 6th, 2025
BMS Pledges $40B Investment in US Despite Cost-Cutting Plans

This year alone BMS has laid off more than 800 employees, the bulk of which were just revealed this month, putting 516 jobs on the chopping block.

ROI-NJ
May 6th, 2025
Bristol Myers Squibb Names Gallman Executive Vp, General Counsel And Chief Policy Officer

Bristol Myers Squibb, the fourth-largest company in New Jersey by market cap, announced Tuesday the appointment of Cari Gallman as executive vice president, general counsel and chief policy officer, effective immediately. She succeeds Sandra (Sandy) Leung, who is retiring after a 33-year career at the company.Gallman has extensive experience in pharmaceutical law and compliance. She will lead the law department, which includes intellectual property, commercial and regulatory law, litigation, securities and corporate governance, transactions, corporate security and compliance and ethics, as well as global and U.S. policy and government affairs. Gallman has held leadership positions at Bristol Myers Squibb for 10 years, most recently serving as executive vice president, corporate affairs.“I am committed to continuing to build on the company’s culture of integrity and shape a dynamic policy environment that protects innovation and patients,” said Gallman in a statement.Gallman began her legal career in private practice representing pharmaceutical and medical device manufacturers in civil, regulatory, and government enforcement matters.She earned a bachelor’s degree in political theory from Princeton University, magna cum laude, and holds a juris doctor degree from Harvard Law School

Endpoints News
May 5th, 2025
Bristol Myers to lay off over 500 workers in New Jersey

Bristol Myers to lay off over 500 workers in New Jersey.

NJBIZ
May 5th, 2025
Bristol Myers Squibb plans 500+ layoffs in NJ

BMS recently announced plans to close a manufacturing facility in Illinois that handles viral vector production.

All Blog Things
May 3rd, 2025
BMS to lay off 516 employees at its Lawrence Township facility

BMS to lay off 516 employees at its Lawrence Township facility.